Amniotics AB (publ)

Symbol: AMNI.ST




Market price today

  • -0.1735

    P/E Ratio

  • 0.0009

    PEG Ratio

  • 10.03M

    MRK Cap

  • 0.00%

    DIV Yield

Amniotics AB (publ) (AMNI-ST) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Marcus Larsson Ph.D.
Full-time employees:6
Address:ScheelevAegen 2

Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.

General Outlook

In simple terms, Amniotics AB (publ) has 2710.55 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -1.193% return, is a testament to Amniotics AB (publ)'s adeptness in optimizing resource deployment. Amniotics AB (publ)'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -3.350%. Furthermore, the proficiency of Amniotics AB (publ) in capital utilization is underscored by a remarkable -2.023% return on capital employed.

Stock Prices

Amniotics AB (publ)'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.0038, while its low point bottomed out at $0.003. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Amniotics AB (publ)'s stock market.

Liquidity Ratios

Analyzing AMNI.ST liquidity ratios reveals its financial health of the firm. The current ratio of 117.28% gauges short-term asset coverage for liabilities. The quick ratio (112.23%) assesses immediate liquidity, while the cash ratio (77.86%) indicates cash reserves.

Current Ratio117.28%
Quick Ratio112.23%
Cash Ratio77.86%

Profitability Ratios

The net income per EBT, 100.00%, and the EBT per EBIT, 99.02%, provide insights into its earnings hierarchy.

Net Income per EBT100.00%
EBT per EBIT99.02%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.17, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding112
Days of Inventory Outstanding101
Inventory Turnover3.61

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.02, and free cash flow per share, -0.02, depict cash generation on a per-share basis. The cash per share value, 0.01, showcases liquidity position.

Operating Cash Flow per Share-0.02
Free Cash Flow per Share-0.02
Cash per Share0.01
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of -17.50 indicates its ability to manage interest expenses.

Interest Coverage-17.50
Company Equity Multiplier1.68

Per Share Data

Net income per share, -0.07, reflects the portion of profit attributed to each share. The book value per share, 0.03, represents the net asset value distributed per share, while the tangible book value per share, 0.03, excludes intangible assets.

Net Income Per Share-0.07
Book Value Per Share0.03
Tangible Book Value Per Share0.03
Shareholders Equity Per Share0.03

Growth Ratios

EBIT growth, 26.36%, and operating income growth, 26.36%, offer insights into operational profitability progression. The net income growth, 37.51%, showcases bottom-line expansion, and the EPS growth, 77.47%, measures the growth in earnings per share.

Gross Profit Growth-28.33%
EBIT Growth26.36%
Operating Income Growth26.36%
Net Income Growth37.51%
EPS Growth77.47%
EPS Diluted Growth77.47%
Weighted Average Shares Growth176.85%
Weighted Average Shares Diluted Growth176.85%
Operating Cash Flow Growth37.01%
Free Cash Flow Growth40.89%
10-Year Operating CF Growth per Share-2180.84%
5-Year Operating CF Growth per Share-2180.84%
3-Year Operating CF Growth per Share81.04%
10-Year Net Income Growth per Share-19.19%
5-Year Net Income Growth per Share-19.19%
3-Year Net Income Growth per Share59.90%
10-Year Shareholders Equity Growth per Share-51.53%
5-Year Shareholders Equity Growth per Share-51.53%
3-Year Shareholders Equity Growth per Share-85.17%
Receivables Growth-43.90%
Inventory Growth8363.70%
Asset Growth-9.79%
Book Value per Share Growth278.47%
Debt Growth-100.00%
SGA Expenses Growth-28.91%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -4,104,804.109, captures the company's total value, considering both debt and equity. Income quality, 0.94, assesses the reliability of reported earnings.

Enterprise Value-4,104,804.109
Income Quality0.94
Graham Number0.23
Return on Tangible Assets-118.34%
Working Capital1,823,000
Tangible Asset Value15,539,000
Net Current Asset Value1,823,000
Average Receivables5,043,500
Average Payables3,822,000
Average Inventory263,769
Days of Inventory On Hand85

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.35, and the price to book ratio, 0.35, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -0.34, and price to operating cash flows, -0.19, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.35
Price to Book Ratio0.35
Price Cash Flow Ratio-0.19
Enterprise Value Multiple-0.62
Price Fair Value0.35
Price to Operating Cash Flow Ratio-0.19
Price to Free Cash Flows Ratio-0.34
Price to Tangible Book Ratio0.26
Enterprise Value Over EBITDA0.13
EV to Operating Cash Flow0.14
Earnings Yield-751.61%
Free Cash Flow Yield-708.29%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Amniotics AB (publ) (AMNI.ST) on the STO in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.173 in 2024.

What is the ticker symbol of Amniotics AB (publ) stock?

The ticker symbol of Amniotics AB (publ) stock is AMNI.ST.

What is company IPO date?

IPO date of Amniotics AB (publ) is 2021-07-06.

What is company current share price?

Current share price is 0.004 SEK.

What is stock market cap today?

The market cap of stock today is 10029035.000.

What is PEG ratio in 2024?

The current 0.001 is 0.001 in 2024.

What is the number of employees in 2024?

In 2024 the company has 6.